Eudragit-based transdermal delivery system of pentazocine: Physico-chemical, in vitro and in vivo evaluations

Pharmaceutical Development and Technology

Volumn 15, Issue 3, 2010, Pages 296-304

  Chandak, Ashok R ^a,b   Prasad Verma, Priya Ranjan ^b  

^a Birla Institute of Technology ^*  (United States)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Cygnus; Eudragit; In vitro and in vivo evaluation; Pentazocine transdermal films; Sandwich patch holder

Indexed keywords

EUDRAGIT; PENTAZOCINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; THICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; WEIGHT; X RAY DIFFRACTION;

EID: 77952080672     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903188501     Document Type: Article

References (22)

1. Sweetman SC. Martindale: The complete drug reference. 33rd ed. London, Chicago: Pharmaceutical Press; 2002:74-75.
2. Mandal SC, Bhattacharyya M, Ghosal SK. In vitro release and permeation kinetics of pentazocine from matrix-dispersion type transdermal drug delivery system. Drug Dev Ind Pharm 1994;20(11):1933-1941.
3. Moffat AC. Clarke's isolation and identification of drugs. 2nd ed. London: Pharmaceutical Press; 1986;860-861.
4. Monkhouse DC, Huq AS. Transdermal drug delivery-problems and promises. Drug Dev Ind Pharm 1988;14:183-203.
5. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv 2006;13:175-187.
6. Kurihara BT, Good WR, Feusullin S, Signor C. Skin compatibility of transdermal drug delivery system. J. Control Release 1991;15:271-278.
7. Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm 2004;58:279-289.
8. Iyer SS, Verma PRP. Controlled transdermal drug delivery of propanolol using HPMC matrices: Design, in vitro and in vivo evaluation. J Pharm Pharmacol 2000;52(2):151-156.
9. Verma PRP, Murthy TEGK. Transdermal flurbiprofen delivery using HPMC matrices: Design, in vitro and in vivo evaluation. Drug Dev Ind Pharm 1997;23(7):633-638.
10. Man M, Chang C, Lee PH, Broman CT, Cleary GW. New improved paddle method for determining the in vitro drug release profiles of transdermal delivery systems. J Control Release 1993;27(1):59-68.
11. Berkowitz B, Way EL. Metabolism and excretion of pentazocine in man. J Clin Pharmacol Ther 1969;10:681-689.
12. Lui J, Xiao Y, Allen C. Polymer-drug compatibility: A guide to the development of delivery system for the anticancer agent. J Pharm Sci 2004;93(1):132-143.
13. Wartewig S, Neubert RHH. Pharmaceutical application of mid-IR and Raman spectroscopy. Adv Drug del Rev 2005;57:1144-1170.
14. Wilson TD. Pentazocine. In: Florey K, editor. Analytical profiles of drug substances. Vol. 13. London: Pharmaceutical Press Inc; 1984;361-416.
15. Varshosaz J, Faghihian H, Rastgoo K. Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Deliv 2006;13:295-302.
16. Chandak AR, Verma PRP. Transdermal delivery of methotrexate using mixed grades of eudragit: Physicochemical, in vitro and in vivo evaluation. Clin Res Reg Affairs 2008;25(2):53-72.
17. Cilurzo F, Minghetti P, Casiraghi A, Tosi L, Pagani S, Montanari L. Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen. Eur J Pharm Biopharm 2005;60:61-66.
18. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
19. Costa P, Sousa-Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-133.
20. Perioli L, Ambrogi V Rubini D, Giovagnoli S, Ricci M, Blasi P, Rossi C. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J Control Release 2004;95:521-533.
21. Mutalik S, Udupa N. Glibenclamide transdermal patches: Physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci 2004;93(6):1577-1594.
22. Rohr UD, Altenburger R, Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering β-estradiol: In vitro/in vivo correlation. Pharm Res 1998;15(6):877-882.